



2018年12月14日 星期五

[首页](#)[期刊概况](#)[编委会](#)[专家学者](#)[网上投稿](#)[过刊浏览](#)[期刊订阅](#)[广告合作](#)

中国肿瘤临床 » 2014, Vol. 41 » Issue (7): 444-448 DOI: doi:10.3969/j.issn. 1000-8179.20131475

[临床研究与应用](#)[最新目录](#) | [下期目录](#) | [过刊浏览](#) | [高级检索](#)[◀◀ 前一篇](#) | [后一篇 ▶▶](#)

## 非小细胞肺癌XIAP和Smac的表达与临床病理特征及预后的关系

叶闻远①, 欧阳学农②, 余宗阳②

作者单位: ①福建医科大学附属福州市第一医院肿瘤内科(福州市350000); ②南京军区福州总医院肿瘤科

### Expression of XIAP and Smac in human non-small-cell lung carcinoma ( NSCLC ) and the relationship with clinical significance and prognosis

Wenyuan YE<sup>1</sup>, Xuenong OUYANG<sup>2</sup>, Zongyang YU<sup>2</sup>

1Department of Medical Oncology, Fuzhou No. 1 Hospital Affiliated to Fujian Medical University,

2Department of Oncology, General Hospital of Fuzhou Military Command, Fuzhou 350025, China.

[摘要](#)[图/表](#)[参考文献\(0\)](#)[相关文章 \(15\)](#)**全文:** [PDF](#) (2343 KB) [HTML](#) (1 KB)**输出:** [BibTeX](#) | [EndNote](#) (RIS)**摘要**

目的: 探讨XIAP(X-linked inhibitor of apoptosis protein, XIAP)和Smac(second mitochondria-derived activator of caspase, Smac)在非小细胞肺癌(non-small cell lung cancer, NSCLC)组织中的表达与临床病理特征及预后的关系。方法: 采用免疫组织化学法检测70例非小细胞肺癌组织及70例对癌旁肺组织中XIAP、Smac的表达。结果: XIAP在70例NSCLC组织中有59例阳性表达, 其中高表达16例; 对应70例癌旁肺组织中有52例表达, 其中高表达5例, 两组XIAP表达强度比较差异有统计学意义( $Z=-4.049$ ,  $P<0.001$ )。Smac在70例肺癌组织中有63例阳性表达, 其中高(强阳性)表达32例; 对应70例癌旁肺组织有53例表达, 其中高(强阳性)表达5例, 两组Smac表达强度比较差异有统计学意义( $Z=-5.484$ ,  $P<0.001$ )。NSCLC组织中XIAP、Smac的表达与患者的性别、年龄、肿瘤大小、组织类型、分化程度、吸烟与否等无明显关系( $P>0.05$ )。但二者的表达均与临床分期、淋巴结转移与否有关系( $P<0.05$ )。通过Kaplan-Meier法分析得出, XIAP和Smac在NSCLC中的表达与患者的预后均无明显关系( $P>0.05$ )。结论: 1) XIAP和Smac在非小细胞肺癌组织及其对应癌旁肺组织中均有表达, 但存在表达量的差异。2) XIAP和Smac在非小细胞肺癌中的表达与患者的预后均无显著关系。

**服务**

- [把本文推荐给朋友](#)
- [加入我的书架](#)
- [加入引用管理器](#)
- [E-mail Alert](#)
- [RSS](#)

**作者相关文章**

- [叶闻远①](#)
- [欧阳学农②](#)
- [余宗阳②](#)

**关键词:** X连锁凋亡抑制蛋白, 第二个线粒体衍生的半胱天冬酶激活蛋白, 非小细胞肺癌, 免疫组化, 预后**Abstract:**

Objective: To investigate the expression of XIAP and Smac in human non-small-cell lung carcinoma (NSCLC) and the relationship with clinical significance and prognosis. Methods: Immunohistochemical staining was performed to determine the ex -pression of X-linked inhibitor of apoptosis protein (XIAP) and second mitochondria-derived activator of caspase (Smac) in 70cases of NSCLC and 70cases of non-cancerous adjacent lung tissues. Results: XIAP is mostly present ( 59/70 ) in tumor tissues with high ex -pressions, whereas only five high expressions in non-cancerous adjacent lung tissues are observed ( 52/70 ). The statistical difference of these two sets of data is significant (  $Z=-5.484$ ,  $P<0.001$  ). Comparatively, Smac is present ( 63/70 ) in tumor tissues, which is significantly higher than in the non-cancerous adjacent lung tissues ( 53/70 ). The expression levels of XIAP and Smac in NSCLC tissues are closely related to the lymph node metastasis at the TNM stages ( $P<0.05$ ) and not associated to gender, age, size of tumor, and differentiation grades ( $P>0.05$ ). The Kaplan-Meier analysis results show that survival by XIAP and Smac protein in NSCLC has no significant effect ( $P>0.05$ ). Conclusion: XIAP and Smac are expressed in NSCLC and noncancerous adjacent lung tissues, and the differences in their expression levels is significant. The deterioration of NSCLC results in apoptosis/anti-apoptotic synchronized with tumor cell proliferation. The expression levels of XIAP and Smac in NSCLC are not related with the prognosis.

**Key words:** X-linked inhibitor of apoptosis protein (XIAP) second mitochondria-derived activator of caspase (Smac) non-small cell lung cancer (NSCLC) immunohistochemistry, prognosis**收稿日期:** 2013-09-04 **出版日期:** 2014-04-15**通讯作者:** 欧阳学农 **E-mail:** oyxn@public.fz.fj.cn**引用本文:**

叶闻远①, 欧阳学农②, 余宗阳②. 非小细胞肺癌XIAP和Smac的表达与临床病理特征及预后的关系[J]. 中国肿瘤临床, 2014, 41(7): 444-448. Wenyuan YE<sup>1</sup>, Xuenong OUYANG<sup>2</sup>, Zongyang YU<sup>2</sup>. Expression of XIAP and Smac in human non-small-cell lung carcinoma ( NSCLC ) and the relationship with clinical significance and prognosis. Chinese Journal of Clinical Oncology, 2014, 41(7): 444-448.

**链接本文:**

<http://www.cjco.cn/CN/doi:10.3969/j.issn. 1000-8179.20131475> 或 <http://www.cjco.cn/CN/Y2014/V41/I7/444>

**友情链接**

版权所有 © 2013 《中国肿瘤临床》编辑部

地址 : 天津市河西区体院北环湖西路肿瘤医院内 300060

电话/传真 : (022)23527053 E-mail: cjco@cjco.cn cjcotj@sina.com 津ICP备09011441号-3